How Can Molecular Imaging Improve My Drug Development Program?
The incorporation of molecular imaging solutions into drug development programs allows investigators to receive rapid results, assess their compound of interest and make critical go/no-go decisions earlier in the development process. At MPI Research, we routinely use cutting-edge technology in molecular imaging and radiochemistry to assist our Sponsors in meeting their development milestones. We offer:
- Integrated small animal imaging: microPET/CT and microSPECT/CT
- Respiratory and cardiac-gated imaging capabilities
- Full-service radiochemistry lab services
- Comprehensive data analysis and interpretation
- “Real-time” determination of pharmacokinetics and pharmacodymanics.
Depth and Breadth of Imaging Experience
MPI Research has significant experience in using platforms/assays such as: integrated PET/CT, SPECT/CT, Quantitative Whole Body Autoradiography (QWBA), and others for visualizing and characterizing molecular, cellular and physiological processes. These technologies, when coupled with the appropriate radionuclide or radiopharmaceutical, provide insight into disease processes and the potential efficacy/safety of new therapeutic targets.
Figure 1. Rodent microSPECT/CT image demonstrating liver update of 99MTc
Figure 2. Correlation of ex vivo (gamma counter) and in vivo (microSPECT) 99MTc liver concentration.
The peer-reviewed article, “Molecular Imaging in Preclinical Research and Drug Development,” provides even more information about how we can assist you in utlilizing molecular imaging and radiochemistry to achieve your research objectives with greater accuracy and efficiency. Contact us at email@example.com to discuss how we can build efficiences in achieving your development milestones with molecular imaging.